Screener
Absci Corporation ABSI Q2 2026 earnings
Reported August 11, 2026 · After market close
Revenue$300.0KMiss by $619.6K
EPS-$0.18Beat by $0.01
Revenue estimate$919.6K
EPS estimate-$0.19
“The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next. We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027. These results have the potential to demonstrate ABS-201's regenerative mechanism and change the treatment paradigm for the millions of people living with pattern hair loss. And this is just the beginning for our prolactin receptor franchise within our overall proprietary pipeline, with endometriosis expansion ahead.”
Next report
Nov 16, 2026 (in 2 months)Revenue estimate$697.6K
EPS estimate-$0.19
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Absci Corporation report Q2 2026 earnings?
- Absci Corporation (ABSI) reported Q2 2026 earnings on August 11, 2026 after market close.
- What were Absci Corporation's Q2 2026 revenue and EPS?
- Absci Corporation reported revenue of $300.0K and eps of $-0.18 for Q2 2026.
- Did Absci Corporation beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $919.6K by $619.6K. EPS beat the consensus estimate of $-0.19 by $0.01.
- How did Absci Corporation's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 49.4% from $593.0K a year earlier and eps grew 25.0% from $-0.24.
- Where can I find Absci Corporation's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001672688-26-000134) and the 10-Q periodic report (0001672688-26-000136) directly on SEC EDGAR. The filing index links above go to sec.gov.
